Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Status:
Terminated
Trial end date:
2016-09-09
Target enrollment:
Participant gender:
Summary
The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone
or in combination with capecitabine for patients with refractory metastatic colorectal cancer
(mCRC) after failure of at least 2 lines of standard treatment